https://doi.org/10.48047/AFJBS.6.16.2024.4231-4237

African Journal of Biological Sciences

Journal homepage: http://www.afjbs.com

Research Paper Open Access

Antimicrobial Resistance in Uropathogens: Challenges in Managing Urinary Tract Infections in Renal Patients

Muhammad Haroon Ghous, Muhammad Farrukh Naveed, Izza Imran, Imran Ahmed Moinuddin, Nusrat Tariq, Muhammad Mazhar, Farah Naz Tahir

1. Professor of Urology, University College of Medicine and Dentistry, University of Lahore, muhammad.haroon1@ucm.uol.edu.pk
2. Senior Registrar, Department of Urology and Renal Transplantation, Bahawal Victoria Hospital, Quaid-i-Azam Medical College, Bahawalpur, Pakistan, drfarrukh138@hotmail.com
3. FCPS Pediatric Medicine, Woman Medical Officer (Consultant), UCHS Lahore, drizzaimran@hotmail.com
4. MBBS, Diplomate American Board of Internal Medicine, Assistant Professor of Medicine, University College of Medicine and Dentistry, Lahore, imranmoin80@yahoo.com
5. M. B. B. S. M. Phil and Ph. D (physiology), M. Islam Medical & Dental College Gujranwala, drnusrattariq@gmail.com.
6. Assistant Professor of Pathology (Microbiology), Pathology Department, Loralai Medical College, Loralai, muhammadmazhar772@gmail.com
7. MBBS, MPhil, PhD, Associate Professor, Biochemistry Department, Central Park Medical College, Lahore, tahirnazfarah@gmail.com

Volume 6, Issue 16, Dec 2024

Received: 13 Aug 2024

Accepted: 11 Nov 2024

Published: 27 Dec 2024

doi:10.48047/AFJBS.6.16.2024.4231-4237

Abstract

Background:

Urinary tract infections (UTIs) are common in renal patients, presenting significant clinical challenges due to impaired immune function and frequent medical interventions. The growing prevalence of antimicrobial resistance (AMR) in uropathogens complicates the treatment of these infections, posing a serious health risk in renal disease populations, including those with chronic kidney disease (CKD), dialysis-dependent patients, and renal transplant recipients. AMR in uropathogens such as *Escherichia coli*, *Klebsiella pneumoniae*, and *Enterococcus faecalis* is an emerging concern, leading to treatment failures and increased morbidity.

Objective:

This study investigates the prevalence of AMR in uropathogens causing UTIs in renal patients, identifies risk factors contributing to resistance, and evaluates alternative treatment strategies in the face of increasing antimicrobial resistance.

Methods:

A prospective cohort study was conducted involving 500 renal patients diagnosed with UTIs at a tertiary care center. Urine samples were cultured, and antimicrobial susceptibility testing was performed to identify resistance patterns. Patient demographics, comorbidities, renal function status, and use of medical devices were recorded. Statistical analysis was performed to determine the association of AMR with clinical factors such as stage of CKD, prior antibiotic use, and presence of indwelling catheters.

Results:

Over 45% of uropathogens were resistant to common first-line antibiotics, with *E. coli* exhibiting the highest resistance. Meropenem and fosfomycin showed the most favorable outcomes in resistant infections, with success rates of 92.3% and 87.5%, respectively. Resistance was significantly higher in patients with advanced CKD and those with catheter use. These results underscore the urgency of developing alternative strategies for managing UTIs in renal patients.

Conclusion:

Antimicrobial resistance is a major challenge in managing UTIs in renal patients. The findings highlight the need for targeted antimicrobial stewardship, surveillance of resistance patterns, and the incorporation of alternative therapies, such as meropenem and fosfomycin, to combat multidrug-resistant infections. Further research is necessary to optimize treatment regimens and improve clinical outcomes for this high-risk population.

Keywords:

Antimicrobial resistance, Uropathogens, Renal patients, Urinary tract infections, Chronic kidney disease, Carbapenems, Fosfomycin, Antibiotic stewardship.

Introduction

Urinary tract infections (UTIs) remain one of the most prevalent infectious diseases globally, affecting individuals of all age groups and contributing to significant healthcare burdens. In patients with renal disease, however, UTIs pose a unique set of challenges, as renal dysfunction alters immune responses and complicates treatment strategies. Moreover, the increasing prevalence of antimicrobial resistance (AMR) in uropathogens has intensified these challenges, particularly in populations with chronic kidney disease (CKD) and those undergoing dialysis or kidney transplantation[1].

The pathogenesis of UTIs in renal patients is multifactorial, involving not only the virulence of the causative microorganisms but also the host's immune response, urinary tract abnormalities, and the presence of indwelling catheters or other medical devices. However, the emergence of AMR complicates the management of these infections, as first-line antibiotics may no longer be effective[2]. The increasing resistance among common uropathogens such as *Escherichia coli*, *Klebsiella pneumoniae*, and *Proteus mirabilis* has led to treatment failures and prolonged hospitalization, thereby increasing the risk of complications, including sepsis and kidney damage. This study seeks to assess the burden of antimicrobial resistance in uropathogens among renal patients, analyze patterns of resistance, and evaluate the efficacy of alternative treatment strategies for managing UTIs in this high-risk population. By focusing on the interplay between renal dysfunction and AMR, this study provides crucial insights into how the growing problem of resistant infections can be addressed in clinical practice[3-8].

Objective

The primary objectives of this study are:

1. To investigate the prevalence of antimicrobial resistance in uropathogens causing urinary tract infections in renal patients.
2. To examine factors contributing to the development and spread of AMR in this population, including renal disease progression, comorbidities, and the use of medical devices.
3. To evaluate the clinical outcomes and effectiveness of various antimicrobial treatments for UTIs in renal patients, focusing on those resistant to first-line therapies.
4. To identify key risk factors for AMR acquisition in renal patients and propose strategies to mitigate resistance.

Methods

This prospective cohort study included 500 renal patients diagnosed with urinary tract infections at University College of Medicine and Dentistry, University of Lahore, tertiary care hospital. Patients were selected based on their medical history, including stages of chronic kidney disease, dialysis status, or post-kidney transplantation. Urine samples were collected and cultured to identify uropathogens responsible for the infections. Antimicrobial susceptibility testing was performed using standard disk diffusion and broth microdilution methods to determine resistance patterns.

Data on patient demographics, comorbid conditions (e.g., diabetes mellitus, hypertension), renal function status, prior antibiotic use, and the presence of indwelling urinary catheters or other devices were collected. The study also included an analysis of patient outcomes, such as the resolution of infection, recurrence rates, and any adverse effects related to treatment.

Antimicrobial resistance was categorized based on the resistance profiles of key uropathogens, including *E. coli*, *K. pneumoniae*, *Enterococcus faecalis*, and *Proteus spp.* The study also examined the use of alternative antibiotics, including carbapenems, fosfomycin, and nitrofurantoin, and evaluated their clinical efficacy.

To assess the impact of renal function on the development of AMR, patients were divided into groups based on their estimated glomerular filtration rate (eGFR). Statistical analysis was performed using SPSS software to determine the significance of various risk factors, including renal disease stage, prior antibiotic use, and the presence of comorbidities, in relation to AMR prevalence and treatment outcomes.

Results

Table 1: Prevalence of Uropathogens in Renal Patients

Uropathogen	**Prevalence (%)**
Escherichia coli	45.6
Klebsiella pneumoniae	22.1
Enterococcus faecalis	12.8
Proteus mirabilis	9.4
Pseudomonas aeruginosa	7.3
Enterobacter spp.	3.8

This table shows the distribution of common uropathogens in renal patients with UTIs. *E. coli* was the most frequently isolated pathogen, followed by *K. pneumoniae* and *Enterococcus faecalis*.

Table 2: Resistance Patterns of Uropathogens

Antibiotic	***E. coli* (%)**	***K. pneumoniae* (%)**	***Enterococcus faecalis* (%)**	***Proteus mirabilis* (%)**
Ampicillin	72.3	65.2	41.4	56.3
Ciprofloxacin	48.5	52.1	33.9	44.5
Trimethoprim-sulfamethoxazole	54.1	59.3	47.8	38.9
Meropenem	10.4	15.7	7.5	5.6
Fosfomycin	18.2	21.1	25.2	27.6

Table 2 presents the resistance patterns of common uropathogens isolated from renal patients. The highest resistance was observed against ampicillin and trimethoprim-sulfamethoxazole. Interestingly, resistance to meropenem, a broad-spectrum carbapenem, was relatively low, indicating its potential utility in treating resistant infections.

Table 3: Treatment Outcomes and Success Rates

Antibiotic Treatment	**Success Rate (%)**	**Failure Rate (%)**
Meropenem	92.3	7.7
Fosfomycin	87.5	12.5
Nitrofurantoin	75.8	24.2
Trimethoprim-sulfamethoxazole	60.9	39.1

Table 3 displays the success and failure rates of various antibiotic treatments. Meropenem showed the highest success rate, followed by fosfomycin. Trimethoprim-sulfamethoxazole demonstrated the lowest success rate, reflecting the high resistance in *E. coli* and *K. pneumoniae*.

Discussion

The results of this study highlight the growing concern of antimicrobial resistance in uropathogens among renal patients. The high prevalence of resistance, particularly to commonly used antibiotics such as ampicillin and trimethoprim-sulfamethoxazole, underscores the need for alternative therapeutic strategies in this vulnerable population. *E. coli* remains the dominant pathogen, but

other resistant organisms such as *Klebsiella pneumoniae* and *Enterococcus faecalis* are increasingly implicated in complicated UTIs, particularly in patients with CKD, dialysis dependence, and those who have undergone renal transplantation[11-13].

Several factors contribute to the development of AMR in renal patients. Chronic kidney disease, which often leads to altered immune function and recurrent hospitalizations, increases the likelihood of exposure to antibiotics, further driving resistance. Moreover, the use of medical devices, such as urinary catheters and dialysis lines, increases the risk of infection with resistant pathogens. These factors make renal patients particularly susceptible to difficult-to-treat infections[14-17].

Our study also examined the efficacy of various antimicrobial agents in treating resistant infections. Meropenem and fosfomycin showed the best outcomes, suggesting they may be effective alternatives for treating multi-drug-resistant uropathogens in renal patients. The lower success rate of nitrofurantoin and trimethoprim-sulfamethoxazole highlights the limitations of these agents in the face of increasing resistance. These findings reinforce the importance of local surveillance of resistance patterns and the need for individualized treatment regimens in renal patients[18-20].

While this study provides valuable insights into the prevalence and management of AMR in renal patients with UTIs, it also highlights the need for improved stewardship of antibiotics. Limiting the overuse of broad-spectrum antibiotics, particularly in hospital settings, is critical to slowing the development of resistance. Furthermore, future research should focus on identifying new therapeutic options, including novel antibiotics or adjunctive therapies, and exploring the role of probiotics in managing UTIs in this patient population.

Conclusion

Antimicrobial resistance in uropathogens presents a significant challenge in managing urinary tract infections in renal patients. The increasing prevalence of resistant organisms, particularly in individuals with chronic kidney disease and those undergoing dialysis or transplantation, calls for a reevaluation of current treatment protocols. Meropenem and fosfomycin appear to be promising alternatives for treating multi-drug-resistant infections, but further research is needed to identify additional therapeutic options. Ultimately, the integration of antimicrobial stewardship practices and a greater focus on prevention will be key in combating this growing threat.

References

1. Pappas PG, et al. Epidemiology of urinary tract infections in renal transplant recipients. *Am J Kidney Dis*. 2022;79(4):523-531.
2. Saxena R, et al. Resistance mechanisms in urinary tract pathogens: Implications for clinical management. *J Clin Microbiol*. 2021;59(6):e00954-21.
3. Sharma S, et al. The role of antimicrobial resistance in urinary tract infections: A comprehensive study. *Clin Microbiol Infect*. 2022;28(2):110-116.
4. Patel S, et al. Antimicrobial resistance in *Escherichia coli* isolates from patients with renal disease: A systematic review. *Nephrol Dial Transplant*. 2023;38(8):1457-1464.
5. Khan A, et al. Uropathogens and their antimicrobial resistance patterns in renal patients: A retrospective analysis. *J Infect Dis*. 2021;223(1):112-118.
6. Liu C, et al. Factors contributing to antimicrobial resistance in renal transplant patients with urinary tract infections. *Transplant Proc*. 2022;54(5):1321-1327.
7. Goetz C, et al. Impact of chronic kidney disease on the prevalence of antibiotic-resistant urinary pathogens. *J Nephrol*. 2021;34(4):657-663.
8. Hossain A, et al. Risk factors for urinary tract infections in dialysis patients: A multicenter study. *Kidney Int*. 2023;104(7):1259-1266.
9. Baid-Agrawal S, et al. Impact of indwelling catheters on urinary tract infection and antimicrobial resistance in renal patients. *Nephrology*. 2022;27(6):406-413.
10. Gupta K, et al. Antimicrobial resistance in *Klebsiella pneumoniae* and *Enterococcus faecalis* isolated from renal patients. *J Urol*. 2021;206(3):601-608.
11. Jenkins H, et al. The evolving role of fosfomycin in the treatment of resistant urinary tract infections in renal patients. *J Antimicrob Chemother*. 2022;77(1):160-167.
12. Mahmoud S, et al. The role of alternative antibiotics in the management of resistant UTIs in renal disease. *Clin Infect Dis*. 2023;67(4):450-456.
13. Allen H, et al. Role of antimicrobial stewardship in reducing resistance in renal patients. *J Hosp Infect*. 2021;117:125-130.
14. Forero L, et al. Resistance patterns of *Escherichia coli* in recurrent urinary tract infections in renal transplant recipients. *Transplant Infect Dis*. 2023;25(2):e13790.
15. Ahmed S, et al. Surveillance of antimicrobial resistance in renal transplant patients with UTIs: A study from Pakistan. *Transplant Infect Dis*. 2022;24(2):e13729.

16. Zhang W, et al. Extended-spectrum beta-lactamase-producing *Klebsiella pneumoniae* in renal patients: An emerging threat. *Microb Drug Resist*. 2022;28(3):268-275.
17. Francheschini F, et al. The role of bacterial biofilms in UTIs in renal patients. *J Infect Dis*. 2021;224(7):1169-1174.
18. McLaughlin R, et al. The association between prior antibiotic use and resistance patterns in renal patients with UTIs. *Nephrol Dial Transplant*. 2022;37(11):1887-1892.
19. Su J, et al. Antimicrobial resistance in *Pseudomonas aeruginosa* in renal disease patients: A national survey. *J Infect Dis*. 2023;228(2):303-310.
20. Wang J, et al. Risk factors for antibiotic resistance in uropathogens isolated from kidney transplant recipients. *Transplant Proc*. 2022;54(4):1150-1156.